Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00807170 | Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases | terminated | Phase 1 | 5 | SanofiINDUSTRY | 1 | Aug 29, 2016 | clinicaltrials |
| NCT00496275 | Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC | completed | Phase 1 | 17 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 26, 2016 | clinicaltrials |
| NCT02126527 | Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Aug 26, 2016 | clinicaltrials |
| NCT02876978 | Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma | unknown | Phase 1 | 20 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT00994123 | A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 162 | Merrimack PharmaceuticalsINDUSTRY | 6 | Aug 22, 2016 | clinicaltrials |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | completed | Phase 1 / Phase 2 | 273 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
| NCT02522910 | An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | Yonsei UniversityOTHER | 0 | Aug 10, 2016 | clinicaltrials |
| NCT01915524 | Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 26 | CureVacINDUSTRY | 3 | Aug 5, 2016 | clinicaltrials |
| NCT01528137 | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer | terminated | Phase 1 | 4 | Stanford UniversityOTHER | 1 | Aug 2, 2016 | clinicaltrials |
| NCT00417248 | Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 8 | Nasser Hanna, M.D.OTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT00826449 | Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 28, 2016 | clinicaltrials |
| NCT01134016 | Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects(Hocena) | completed | Phase 1 | 13 | Golden Biotechnology CorporationINDUSTRY | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT02040064 | Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients(GEFTREM) | completed | Phase 1 | 27 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 9, 2016 | clinicaltrials |
| NCT01666977 | Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AmgenINDUSTRY | 6 | Jun 3, 2016 | clinicaltrials |
| NCT00933777 | SORAVE - Sorafenib and Everolimus in Solid Tumors(SORAVE) | completed | Phase 1 | 36 | University of CologneOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT02651441 | D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC) | unknown | Phase 1 / Phase 2 | 60 | Shenzhen Hornetcorn Bio-technology Company, LTDINDUSTRY | 1 | May 24, 2016 | clinicaltrials |
| NCT01115790 | A Phase 1 Study in Participants With Advanced Cancer | completed | Phase 1 | 150 | Eli Lilly and CompanyINDUSTRY | 1 | May 10, 2016 | clinicaltrials |
| NCT00555256 | A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)(SU/Rapamycin) | completed | Phase 1 | 19 | Washington University School of MedicineOTHER | 1 | May 6, 2016 | clinicaltrials |
| NCT02728492 | Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | completed | Phase 1 | 51 | NewVac LLCINDUSTRY | 1 | May 3, 2016 | clinicaltrials |
| NCT00692380 | Gated Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable NSCLC | terminated | Phase 1 | 28 | Virginia Commonwealth UniversityOTHER | 1 | May 2, 2016 | clinicaltrials |
| NCT02737735 | The Effect on Decreasing Chemotherapeutic Toxicity and Increasing Anti-tumor Effect of Chinese Herbs Based on Syndrome Differentiation | unknown | Phase 1 | 200 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT00690963 | Individual Boosting in Non-Small Cell Lung Cancer Using Hypofractionation, Intensity-modulated Radiation Therapy and Respiratory Gating | unknown | Phase 1 / Phase 2 | 12 | AHS Cancer Control AlbertaOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT00729742 | Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008) | completed | Phase 1 | 49 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 4, 2016 | clinicaltrials |
| NCT00094835 | Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 51 | AmgenINDUSTRY | 0 | Mar 24, 2016 | clinicaltrials |
| NCT00888823 | Phase I/II Study of Fractionated Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 13 | AHS Cancer Control AlbertaOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT00683904 | Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 12 | R-PharmINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00129012 | Self-Gated Breath-Hold Technique for Helical Tomotherapy in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 | 30 | AHS Cancer Control AlbertaOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02691871 | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR | unknown | Phase 1 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT01565772 | Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer | terminated | Phase 1 | 4 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT02537561 | Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Feb 11, 2016 | clinicaltrials |
| NCT00423449 | Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058) | completed | Phase 1 | 61 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 4, 2016 | clinicaltrials |
| NCT01684111 | An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)(VENUS-1) | completed | Phase 1 | 7 | Aktion Bronchialkarzinom e.V.OTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT00534027 | A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 172 | AmgenINDUSTRY | 0 | Jan 14, 2016 | clinicaltrials |
| NCT00779389 | Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family | completed | Phase 1 | 58 | University of PittsburghOTHER | 1 | Jan 13, 2016 | clinicaltrials |
| NCT01411098 | Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | terminated | Phase 1 | 6 | University of WashingtonOTHER | 1 | Nov 4, 2015 | clinicaltrials |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Erin BertinoOTHER | 0 | Oct 30, 2015 | clinicaltrials |
| NCT00162318 | A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 | 30 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00207116 | An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma | completed | Phase 1 | 120 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00768755 | Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 180 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00965731 | Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer | completed | Phase 1 | 27 | PfizerINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01121575 | A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer | completed | Phase 1 | 70 | PfizerINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT00960115 | Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | completed | Phase 1 / Phase 2 | 178 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 21, 2015 | clinicaltrials |
| NCT01100931 | A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) | completed | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2015 | clinicaltrials |
| NCT02507375 | A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 17 | Hoffmann-La RocheINDUSTRY | 3 | Oct 16, 2015 | clinicaltrials |
| NCT02134886 | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection | terminated | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01004419 | Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | University of Wisconsin, MadisonOTHER | 0 | Oct 2, 2015 | clinicaltrials |
| NCT01090011 | Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer | completed | Phase 1 | 171 | Boehringer IngelheimINDUSTRY | 2 | Oct 2, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Aug 29, 2016source: clinicaltrials